NCT06982222 2026-03-19
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
Clinical Trials
26 trialsNCT07483970 2026-03-19
JL19001-NMIBC
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Not yet recruiting
NCT07484022 2026-03-19
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Not yet recruiting
NCT07419841 2026-03-16
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Not yet recruiting
NCT07140315 2026-03-12
DK222 Study at Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Not yet recruiting
NCT07468396 2026-03-12
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
Gan & Lee Pharmaceuticals.
Phase 1 Not yet recruiting
NCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07401875 2026-02-27
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT05521698 2026-02-17
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Not yet recruiting
NCT07297667 2026-02-13
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1 Not yet recruiting
NCT07316686 2026-01-05
Lutécio
Instituto do Cancer do Estado de São Paulo
Phase 1 Not yet recruiting
NCT07145177 2025-12-18
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Not yet recruiting
NCT07260162 2025-12-03
PERSEVERANCE
Institut Cancerologie de l'Ouest
Phase 1 Not yet recruiting
NCT07252661 2025-11-28
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
Phase 1 Not yet recruiting
NCT07244393 2025-11-24
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Cellbion Co., Ltd.
Phase 1 Not yet recruiting
NCT07187869 2025-09-23
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07177937 2025-09-22
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1 Not yet recruiting
NCT06705686 2025-09-05
PHAROS
TechnoGenesys, Inc.
Phase 1 Not yet recruiting
NCT07090369 2025-07-29
LumOnate
Peter MacCallum Cancer Centre, Australia
Phase 1 Not yet recruiting
NCT07053735 2025-07-08
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
Peking University First Hospital
Phase 1 Not yet recruiting
NCT07054307 2025-07-08
MH-Penile-001
West China Hospital
Phase 1 Not yet recruiting
NCT06866795 2025-03-10
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Geode Therapeutics Inc.
Phase 1 Not yet recruiting
NCT06614751 2024-09-27
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Danatlas Pharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT06237491 2024-07-24
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection
Yantai LNC Biotechnology Singapore PTE. LTD.
Phase 1 Not yet recruiting
NCT05979909 2023-08-07
Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
McMaster University
Phase 1 Not yet recruiting
NCT05698238 2023-03-15
CAMP1
Mabpro, a.s.
Phase 1 Not yet recruiting